Our top pick for
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
American Renal Associates Holdings Inc is a diagnostics & research business based in the US. American Renal Associates shares (ARA) are listed on the NYSE and all prices are listed in US Dollars. American Renal Associates employs 4,977 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$11.33 - $11.52|
|50-day moving average||$11.47|
|200-day moving average||$9.70|
|Wall St. target price||$10.00|
|Dividend yield||$1.3 (11.3%)|
|Earnings per share (TTM)||$-0.67|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing American Renal Associates stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of American Renal Associates's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
American Renal Associates's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into American Renal Associates's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
American Renal Associates's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $113.5 million.
The EBITDA is a measure of a American Renal Associates's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$814.1 million|
|Operating margin TTM||9.73%|
|Gross profit TTM||$254.5 million|
|Return on assets TTM||4.35%|
|Return on equity TTM||17.51%|
|Market capitalisation||$397.9 million|
TTM: trailing 12 months
We're not expecting American Renal Associates to pay a dividend over the next 12 months.
Over the last 12 months, American Renal Associates's shares have ranged in value from as little as $11.33 up to $11.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while American Renal Associates's is 1.1062. This would suggest that American Renal Associates's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts. .
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.